FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3172359983> ?p ?o ?g. }

• W3172359983 endingPage "246" @default.
• W3172359983 startingPage "242" @default.
• W3172359983 abstract "Given the poor treatment options for pulmonary arterial hypertension associated systemic sclerosis (SSc-PAH) patients, we sought to determine clinical safety and efficacy of Dimethylfumarate (DMF), an Nrf2 agonist, and the effects on biomarkers of oxidative stress on SSc-PAH in an exploratory interventional clinical trial.The primary objectives were to assess the safety and efficacy of treatment with DMF in patients with SSc-PAH.This was an investigator-initiated, double-blind, randomized, placebo-controlled trial conducted at two sites in the United States. The primary safety endpoint was the incidence of serious adverse events (SAEs) and all adverse events (AEs) in DMF compared to placebo-treated patients. The primary efficacy endpoint was the change in 6MWD from baseline to the end of treatment at Week 24 in DMF compared to placebo-treated patients.Six participants were randomized to either placebo (n = 2) or DMF (n = 4). Baseline demographics were similar in both groups. A total of 25 adverse events (AEs) occurred in 6 subjects, with 14 AEs (56.0%) having occurred in DMF-treated subjects. 3 occurrences were identified as nausea AEs, and two participants withdrew due to nausea. One participant in the placebo group was withdrawn after a hospitalization SAE due to worsening of heart failure and shortness of breath secondary to anemia. One participant in each group completed protocol. Subjects in the DMF-treated group showed a non-significant reduced decline in 6MWD (relative mean change of -7.07%) from baseline to Week 24 as compared to placebo-treated subjects (relative mean change of -14.97%).Patients treated for SSc-PAH with 2 and 3-drug regimens, as is now typical for these patients, tolerate DMF poorly. Our small samples size did not provide power to suggest efficacy. We suggest that Nrf2 is still a valid therapeutic target for future trials, using better tolerated Nrf2 agonists." @default.
• W3172359983 created "2021-06-22" @default.
• W3172359983 creator A5017257299 @default.
• W3172359983 creator A5020761483 @default.
• W3172359983 creator A5022673823 @default.
• W3172359983 creator A5032869220 @default.
• W3172359983 creator A5042092283 @default.
• W3172359983 creator A5043432146 @default.
• W3172359983 creator A5045723901 @default.
• W3172359983 creator A5048437803 @default.
• W3172359983 creator A5053913643 @default.
• W3172359983 creator A5068497654 @default.
• W3172359983 creator A5070717609 @default.
• W3172359983 creator A5076627885 @default.
• W3172359983 creator A5077574387 @default.
• W3172359983 creator A5089758720 @default.
• W3172359983 date "2021-05-28" @default.
• W3172359983 modified "2023-10-11" @default.
• W3172359983 title "A pilot study of dimethyl fumarate in pulmonary arterial hypertension associated with systemic sclerosis" @default.
• W3172359983 cites W1972403093 @default.
• W3172359983 cites W1981266729 @default.
• W3172359983 cites W1989353916 @default.
• W3172359983 cites W1992987263 @default.
• W3172359983 cites W2008448835 @default.
• W3172359983 cites W2042987279 @default.
• W3172359983 cites W2057907220 @default.
• W3172359983 cites W2058355050 @default.
• W3172359983 cites W2086531073 @default.
• W3172359983 cites W2089755573 @default.
• W3172359983 cites W2093090071 @default.
• W3172359983 cites W2109462192 @default.
• W3172359983 cites W2138124880 @default.
• W3172359983 cites W2138830055 @default.
• W3172359983 cites W2138884788 @default.
• W3172359983 cites W2799971001 @default.
• W3172359983 cites W2957289901 @default.
• W3172359983 cites W2962391519 @default.
• W3172359983 cites W840875033 @default.
• W3172359983 doi "https://doi.org/10.1177/23971983211016196" @default.
• W3172359983 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35005243" @default.
• W3172359983 hasPublicationYear "2021" @default.
• W3172359983 type Work @default.
• W3172359983 sameAs 3172359983 @default.
• W3172359983 citedByCount "4" @default.
• W3172359983 countsByYear W31723599832022 @default.
• W3172359983 countsByYear W31723599832023 @default.
• W3172359983 crossrefType "journal-article" @default.
• W3172359983 hasAuthorship W3172359983A5017257299 @default.
• W3172359983 hasAuthorship W3172359983A5020761483 @default.
• W3172359983 hasAuthorship W3172359983A5022673823 @default.
• W3172359983 hasAuthorship W3172359983A5032869220 @default.
• W3172359983 hasAuthorship W3172359983A5042092283 @default.
• W3172359983 hasAuthorship W3172359983A5043432146 @default.
• W3172359983 hasAuthorship W3172359983A5045723901 @default.
• W3172359983 hasAuthorship W3172359983A5048437803 @default.
• W3172359983 hasAuthorship W3172359983A5053913643 @default.
• W3172359983 hasAuthorship W3172359983A5068497654 @default.
• W3172359983 hasAuthorship W3172359983A5070717609 @default.
• W3172359983 hasAuthorship W3172359983A5076627885 @default.
• W3172359983 hasAuthorship W3172359983A5077574387 @default.
• W3172359983 hasAuthorship W3172359983A5089758720 @default.
• W3172359983 hasBestOaLocation W31723599832 @default.
• W3172359983 hasConcept C118552586 @default.
• W3172359983 hasConcept C120665830 @default.
• W3172359983 hasConcept C121332964 @default.
• W3172359983 hasConcept C126322002 @default.
• W3172359983 hasConcept C141071460 @default.
• W3172359983 hasConcept C142724271 @default.
• W3172359983 hasConcept C197934379 @default.
• W3172359983 hasConcept C203092338 @default.
• W3172359983 hasConcept C204787440 @default.
• W3172359983 hasConcept C27081682 @default.
• W3172359983 hasConcept C2776819417 @default.
• W3172359983 hasConcept C2778375690 @default.
• W3172359983 hasConcept C2780580376 @default.
• W3172359983 hasConcept C2780640218 @default.
• W3172359983 hasConcept C535046627 @default.
• W3172359983 hasConcept C61511704 @default.
• W3172359983 hasConcept C71924100 @default.
• W3172359983 hasConceptScore W3172359983C118552586 @default.
• W3172359983 hasConceptScore W3172359983C120665830 @default.
• W3172359983 hasConceptScore W3172359983C121332964 @default.
• W3172359983 hasConceptScore W3172359983C126322002 @default.
• W3172359983 hasConceptScore W3172359983C141071460 @default.
• W3172359983 hasConceptScore W3172359983C142724271 @default.
• W3172359983 hasConceptScore W3172359983C197934379 @default.
• W3172359983 hasConceptScore W3172359983C203092338 @default.
• W3172359983 hasConceptScore W3172359983C204787440 @default.
• W3172359983 hasConceptScore W3172359983C27081682 @default.
• W3172359983 hasConceptScore W3172359983C2776819417 @default.
• W3172359983 hasConceptScore W3172359983C2778375690 @default.
• W3172359983 hasConceptScore W3172359983C2780580376 @default.
• W3172359983 hasConceptScore W3172359983C2780640218 @default.
• W3172359983 hasConceptScore W3172359983C535046627 @default.
• W3172359983 hasConceptScore W3172359983C61511704 @default.
• W3172359983 hasConceptScore W3172359983C71924100 @default.
• W3172359983 hasFunder F4320337362 @default.
• W3172359983 hasIssue "3" @default.

• next